Rapid testing versus karyotyping in Down's syndrome screening: cost-effectiveness and detection of clinically significant chromosome abnormalities
Authors:
Open Access
- 15 September 2010
- journal article
- research article
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 19 (1) , 3-9
Abstract
In all, 80% of antenatal karyotypes are generated by Down's syndrome screening programmes (DSSP). After a positive screening, women are offered prenatal foetus karyotyping, the gold standard. Reliable molecular methods for rapid aneuploidy diagnosis (RAD: fluorescence in situ hybridization (FISH) and quantitative fluorescence PCR (QF-PCR)) can detect common aneuploidies, and are faster and less expensive than karyotyping. In the UK, RAD is recommended as a standalone approach in DSSP, whereas the US guidelines recommend that RAD be followed up by karyotyping. A cost-effectiveness (CE) analysis of RAD in various DSSP is lacking. There is a debate over the significance of chromosome abnormalities (CA) detected with karyotyping but not using RAD. Our objectives were to compare the CE of RAD versus karyotyping, to evaluate the clinically significant missed CA and to determine the impact of detecting the missed CA. We performed computer simulations to compare six screening options followed by FISH, PCR or karyotyping using a population of 110 948 pregnancies. Among the safer screening strategies, the most cost-effective strategy was contingent screening with QF-PCR (CE ratio of $24 084 per Down's syndrome (DS) detected). Using karyotyping, the CE ratio increased to $27 898. QF-PCR missed only six clinically significant CA of which only one was expected to confer a high risk of an abnormal outcome. The incremental CE ratio (ICER) to find the CA missed by RAD was $66 608 per CA. These costs are much higher than those involved for detecting DS cases. As the DSSP are mainly designed for DS detection, it may be relevant to question the additional costs of karyotyping.Keywords
This publication has 49 references indexed in Scilit:
- Consensus Statement: Chromosomal Microarray Is a First-Tier Clinical Diagnostic Test for Individuals with Developmental Disabilities or Congenital AnomaliesThe American Journal of Human Genetics, 2010
- Comparison of different strategies in prenatal screening for Down's syndrome: cost effectiveness analysis of computer simulationBMJ, 2009
- Costs of prenatal genetic screeningThe Lancet, 2008
- Prenatal screening for Down's syndrome: editorial responsibilitiesThe Lancet, 2008
- Survey of prenatal screening policies in Europe for structural malformations and chromosome anomalies, and their impact on detection and termination rates for neural tube defects and Down’s syndromeBJOG: An International Journal of Obstetrics & Gynaecology, 2008
- Sequential and contingent prenatal screening for Down syndromePrenatal Diagnosis, 2006
- First-Trimester or Second-Trimester Screening, or Both, for Down's SyndromeNew England Journal of Medicine, 2005
- Cost-Effectiveness Analysis of Prenatal Diagnosis: Methodological Issues and ConcernsGynecologic and Obstetric Investigation, 2005
- Fetal loss in Down syndrome pregnanciesPrenatal Diagnosis, 1999
- Randomised study of risk of fetal loss related to early amniocentesis versus chorionic villus samplingThe Lancet, 1997